
Francesca Bovis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4226541/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103358.	2.0	33
2	Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscular Disorders, 2022, 32, 36-42.	0.6	13
3	Hyaluronic acidâ€sperm selection significantly improves the clinical outcome of couples with previous ICSI cycles failure. Andrology, 2022, 10, 677-685.	3.5	5
4	Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine. Headache, 2022, 62, 176-190.	3.9	15
5	Hammersmith Infant Neurological Examination in lowâ€risk infants born very preterm: a longitudinal prospective study. Developmental Medicine and Child Neurology, 2022, 64, 863-870.	2.1	11
6	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	9
7	Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients. Cephalalgia, 2022, 42, 827-845.	3.9	9
8	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. Frontiers in Immunology, 2022, 13, 847816.	4.8	2
9	Clinical characterization, long-term follow-up, and response to treatment of patients with syndrome of undifferentiated recurrent fever (SURF). Seminars in Arthritis and Rheumatism, 2022, 55, 152024.	3.4	8
10	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
11	Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	8
12	Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach. JAMA Neurology, 2022, 79, 821.	9.0	5
13	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. Multiple Sclerosis Journal, 2021, 27, 706-711.	3.0	6
14	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	3.8	16
15	Occurrence of smooth endoplasmic reticulum aggregates in metaphase II oocytes: relationship with stimulation protocols and outcome of ICSI and IVF cycles. Human Reproduction, 2021, 36, 907-917.	0.9	16
16	Snoring and Sleep-Related Symptoms: A Novel Non-Invasive 808 nm Wavelength Diode Laser Non-Ablative Outpatient Treatment. A Prospective Pilot-Study on 45 Patients. Photonics, 2021, 8, 69.	2.0	1
17	The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. Rheumatology, 2021, , .	1.9	4
18	Pronuclear score improves prediction of embryo implantation success in ICSI cycles. BMC Pregnancy and Childbirth, 2021, 21, 361.	2.4	3

#	Article	IF	CITATIONS
19	Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1622-1634.	3.7	27
20	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.6	0
21	Oral Antioxidant Treatment of Men Significantly Improves the Reproductive Outcome of IVF Cycles. Journal of Clinical Medicine, 2021, 10, 3254.	2.4	13
22	Disability, burden, and symptoms related to sensitization in migraine patients associate with headache frequency. Scandinavian Journal of Pain, 2021, 21, 766-777.	1.3	10
23	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle and Nerve, 2021, 64, 552-559.	2.2	18
24	Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 54, 103118.	2.0	5
25	Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis. Journal of Clinical Medicine, 2021, 10, 463.	2.4	6
26	Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet Journal of Rare Diseases, 2021, 16, 430.	2.7	58
27	A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1064-1073.	3.0	14
28	Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	3.0	38
29	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology, 2020, 59, 344-360.	1.9	36
30	Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling. Multiple Sclerosis Journal, 2020, 26, 1828-1836.	3.0	14
31	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
32	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. PLoS ONE, 2020, 15, e0240550.	2.5	2
33	Functional Ability and Healthâ€Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	3.4	4
34	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	30
35	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp> . Annals of Neurology, 2020, 88, 1109-1117.	5.3	34
36	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. Microorganisms, 2020, 8, 2010.	3.6	8

#	Article	IF	CITATIONS
37	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. Microorganisms, 2020, 8, 864.	3.6	7
38	Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 174.	4.8	11
39	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	1.9	16
40	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	3.5	25
41	Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies. JAMA Neurology, 2020, 77, 902.	9.0	3
42	Determinants of therapy switch in multiple sclerosis treatment-naÃ⁻ve patients: A real-life study. Multiple Sclerosis Journal, 2019, 25, 1263-1272.	3.0	36
43	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1357-1362.	0.9	74
44	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 36, 101430.	2.0	23
45	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	1.9	10
46	Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle and Nerve, 2019, 59, 426-430.	2.2	61
47	Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. BMC Medicine, 2019, 17, 113.	5.5	13
48	Non-invasive mitochondrial DNA quantification on Day 3 predicts blastocyst development: a prospective, blinded, multi-centric study. Molecular Human Reproduction, 2019, 25, 527-537.	2.8	13
49	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
50	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
51	FRI0568â€THE USE OF NEXT GENERATION SEQUENCING PANEL IN UNDIFFERENTIATED AUTOINFLAMMATORY DISEASES IDENTIFY A SEPARATE SUBSET OF COLCHICINE-RESPONDER RECURRENT FEVERS DISTINCT FROM PFAPA SYNDROME. , 2019, , .		3
52	Management of acute ischemic stroke, thrombolysis rate, and predictors of clinical outcome. Neurological Sciences, 2019, 40, 319-326.	1.9	24
53	Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2019, 25, 217-223.	3.0	5
54	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. Epidemiology and Infection, 2018, 146, 606-611.	2.1	12

#	Article	IF	CITATIONS
55	The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 235-242.	3.0	1
56	The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 59-66.	3.0	0
57	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 51-58.	3.0	Ο
58	The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 227-233.	3.0	0
59	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 395-402.	3.0	4
60	The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 387-393.	3.0	1
61	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 363-369.	3.0	0
62	The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 107-113.	3.0	0
63	The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 243-250.	3.0	1
64	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 283-289.	3.0	0
65	The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 27-33.	3.0	4
66	The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 99-105.	3.0	0
67	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
68	Outpatient erbium:YAG (2940Ânm) laser treatment for snoring: a prospective study on 40 patients. Lasers in Medical Science, 2018, 33, 399-406.	2.1	13
69	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	3.4	19
70	The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 275-282.	3.0	0
71	The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 347-354.	3.0	0
72	The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 371-377.	3.0	0

#	Article	IF	CITATIONS
73	The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 19-26.	3.0	2
74	The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 187-194.	3.0	0
75	The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 83-90.	3.0	1
76	The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 115-122.	3.0	0
77	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 147-153.	3.0	Ο
78	The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 179-186.	3.0	0
79	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 211-218.	3.0	2
80	The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 219-226.	3.0	1
81	The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 171-178.	3.0	1
82	The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 291-298.	3.0	0
83	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 307-313.	3.0	Ο
84	The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 315-321.	3.0	0
85	The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 331-338.	3.0	Ο
86	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 139-146.	3.0	2
87	The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 91-98.	3.0	0
88	The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 43-49.	3.0	8
89	The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 403-409.	3.0	5
90	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 35-42.	3.0	8

#	Article	IF	CITATIONS
91	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatology International, 2018, 38, 5-17.	3.0	74
92	The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 131-138.	3.0	0
93	The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 163-169.	3.0	0
94	The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 155-161.	3.0	6
95	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	3.0	0
96	The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 203-209.	3.0	0
97	The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 259-265.	3.0	0
98	The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 355-361.	3.0	0
99	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	3.0	0
100	The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 67-73.	3.0	3
101	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285.	3.5	71
102	Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. Annals of Neurology, 2018, 84, 621-625.	5.3	26
103	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biology of Blood and Marrow Transplantation, 2018, 24, 2501-2508.	2.0	17
104	The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 75-82.	3.0	7
105	The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 267-274.	3.0	8
106	The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 299-306.	3.0	5
107	The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 323-329.	3.0	0
108	The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 123-130.	3.0	0

#	Article	IF	CITATIONS
109	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 339-346.	3.0	0
110	Impact of acute-phase complications and interventions on 6-month survival after stroke. A prospective observational study. PLoS ONE, 2018, 13, e0194786.	2.5	11
111	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	2.5	6
112	Threeâ€Ðimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease. Journal of Neuroimaging, 2017, 27, 613-619.	2.0	17
113	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50
114	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	3.4	52
115	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2016, 68, 1346-1353.	3.4	22
116	A Metaâ€Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	5.6	11
117	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	2.1	35
118	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	5.6	427
119	Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study. Journal of Alzheimer's Disease, 2016, 53, 505-515.	2.6	27
120	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57
121	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
122	Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2016, 6, 57-63.	2.0	41
123	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
124	Methods of Implementation of Evidence-Based Stroke Care in Europe. Stroke, 2015, 46, 2252-2259.	2.0	8
125	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
126	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Threeâ€Variable Juvenile Arthritis Disease Activity Score. Arthritis Care and Research, 2014, 66, 1703-1709.	3.4	115

#	Article	IF	CITATIONS
127	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
128	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
129	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2871-2880.	5.6	101
130	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 1416-1425.	2.0	25
131	A Long-Term Prognostic Value of CT Angiography and Exercise ECG in Patients With Suspected CAD. JACC: Cardiovascular Imaging, 2013, 6, 641-650.	5.3	42
132	Vascular factors predict polyneuropathy in a non-diabetic elderly population. Neurological Sciences, 2013, 34, 955-962.	1.9	13
133	Role of Alveolar β2-Adrenergic Receptors on Lung Fluid Clearance and Exercise Ventilation in Healthy Humans. PLoS ONE, 2013, 8, e61877.	2.5	29
134	Coronary In-Stent Restenosis: Assessment with CT Coronary Angiography. Radiology, 2012, 265, 410-417.	7.3	45
135	Radiation dose and diagnostic accuracy of multidetector computed tomography for the detection of significant coronary artery stenoses. International Journal of Cardiology, 2012, 160, 155-164.	1.7	24
136	Aortic annulus area assessment by multidetector computed tomography for predicting paravalvular regurgitation in patients undergoing balloon-expandable transcatheter aortic valve implantation. American Heart Journal, 2012, 164, 576-584.	2.7	40